Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

What FDA Requires in an Electronic Document Management System

  • Post author:PacConAdmin
  • Post published:August 21, 2024
  • Post category:Uncategorized

This excerpt is from the management report titled “Managing Data and Documentation for FDA Inspections and Remote Assessments,” based on a webinar from FDAnews, A WCG Company. The presenter was…

Continue ReadingWhat FDA Requires in an Electronic Document Management System

Quick Notes: Drug News and Approvals — Aug. 21, 2024

  • Post author:PacConAdmin
  • Post published:August 21, 2024
  • Post category:Uncategorized

This edition of Quick Notes features a CRL for Lykos Therapeutics NDA for midomafetamine for treating post-traumatic stress disorder and approvals for Amneal’s Crexont, Novartis’ Fabhalta and Citius Pharmaceuticals’ Lymphir.…

Continue ReadingQuick Notes: Drug News and Approvals — Aug. 21, 2024

GAO Says Challenges Remain for FDA Monitoring of Postmarket Devices

  • Post author:PacConAdmin
  • Post published:August 21, 2024
  • Post category:Uncategorized

The FDA’s efforts to actively oversee the safety of medical devices after they’ve hit the market have begun to bear fruit, with the agency making strides toward setting up a…

Continue ReadingGAO Says Challenges Remain for FDA Monitoring of Postmarket Devices

FTC Supports FDA’s Proposal for Interchangeable Biosimilar Substitution

  • Post author:PacConAdmin
  • Post published:August 21, 2024
  • Post category:Uncategorized

The FTC has submitted a comment supporting the FDA draft guidance on interchangeable biosimilar drugs saying that the recommendations in the guidance would increase patient access to lower-cost prescription medications.…

Continue ReadingFTC Supports FDA’s Proposal for Interchangeable Biosimilar Substitution

Quick Notes: Medical Device Clearances and Approvals — Aug. 20, 2024

  • Post author:PacConAdmin
  • Post published:August 20, 2024
  • Post category:Uncategorized

In this edition of Quick Notes, we cover FDA nods for a new sterilization method for duodenoscopes, an updated device for sleep apnea, a smaller continuous glucose monitor and a…

Continue ReadingQuick Notes: Medical Device Clearances and Approvals — Aug. 20, 2024

FDA Clarifies Approach to Product-Specific Guidance Meetings for ANDAs

  • Post author:PacConAdmin
  • Post published:August 20, 2024
  • Post category:Uncategorized

The FDA has finalized advice for generic drug sponsors on seeking meetings with the agency to discuss the impact of a new or revised product-specific guidance (PSG) on their ANDA…

Continue ReadingFDA Clarifies Approach to Product-Specific Guidance Meetings for ANDAs

Eli Lilly’s Zepbound Found to Have Additional Clinical Benefits in New Study

  • Post author:PacConAdmin
  • Post published:August 20, 2024
  • Post category:Uncategorized

A cohort study recently published in JAMA Network Open has found that Eli Lilly’s blockbuster antidiabetic drug Zepbound (tirzepatide) is linked to lower risks of major complications compared to GLP-1…

Continue ReadingEli Lilly’s Zepbound Found to Have Additional Clinical Benefits in New Study

At-Home OTC Syphilis Test Gets FDA De Novo Marketing Nod

  • Post author:PacConAdmin
  • Post published:August 20, 2024
  • Post category:Uncategorized

The FDA has given marketing authorization for a novel device for at home syphilis testing using a single drop of blood. Source: Drug Industry Daily

Continue ReadingAt-Home OTC Syphilis Test Gets FDA De Novo Marketing Nod

Legislative Update — Week of Aug. 19, 2024

  • Post author:PacConAdmin
  • Post published:August 19, 2024
  • Post category:Uncategorized

During the second session of the 118th Congress, FDAnews will track important pending legislation, that has been acted on by Dec. 31, 2023, to keep you updated on laws and…

Continue ReadingLegislative Update — Week of Aug. 19, 2024

Quick Notes: Drug Approvals — Aug. 19, 2024

  • Post author:PacConAdmin
  • Post published:August 19, 2024
  • Post category:Uncategorized

This edition of Quick Notes features approvals for Adaptimmune’s Tecelra, Purdue Pharma’s Zurnai, Servier Pharmaceuticals’ Voranigo and Aurobindo’s Estradiol. Source: Drug Industry Daily

Continue ReadingQuick Notes: Drug Approvals — Aug. 19, 2024
  • Go to the previous page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 143
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company